Japanese generics giant Sawai appears to be turning a corner, but the impact of National Health Insurance pricing revisions continues to hold the firm – and the rest of the country’s generics industry – back.

New supplies of Shionogi's antiviral Xofluza will be used to boost Japan's national stocks of flu therapeutics, along with others including Tamiflu and Relenza, to increase preparedness for new viral strains. While resistance concerns for Xofluza appear to be reducing, local experts supported the decision on condition use is limited to those under 12 years of age.

Mithra’s new CEO has immediately signaled a potential sale for the firm’s generics business as it looks to focus on branded assets in women’s health. Meanwhile, Sawai has reorganized its management team, the longtime chair of Viatris is moving on to another role, and a former AAM vice-president has joined Sandoz.

Aspect says its bioprinted tissue therapeutics include immune-resistant encapsulation, which Novo Nordisk hopes will offer a safer approach to type 1 diabetes cell therapy.